Category: Include on Menu
-
U.S. iPhone upgrade interest at its lowest level in five years, UBS survey shows
Apple (NASDAQ:AAPL) is seeing weakening iPhone purchase intent in the U.S., according to new data from UBS Evidence Lab, even as interest in China unexpectedly improved. The survey, which gathered responses from more than 7,500 smartphone users across five major markets, found that 12-month U.S. iPhone purchase intent slid by roughly 400 basis points to…
-
Chipotle gains after approving $1.8 billion in additional share buybacks
Chipotle Mexican Grill (NYSE:CMG) climbed 2.5% on Monday after disclosing that its Board of Directors approved another $1.8 billion for share repurchases. According to the company’s SEC filing, the authorization—approved on December 4—brings Chipotle’s total remaining buyback capacity to roughly $1.85 billion as of December 5. The move signals a shift in Chipotle’s capital-return strategy.…
-
Castellum rallies after landing key Missile Defense Agency SHIELD contract positions
Castellum, Inc. (AMEX:CTM) rose 5.3% on Monday following news that the company’s subsidiary and joint-venture partners secured spots on the Missile Defense Agency’s SHIELD Multiple Award IDIQ contract vehicle. The cybersecurity and electronic-warfare services firm said that Specialty Systems, Inc., CTM Joint Venture, the C-K2 mentor-protégé JV, and the Epic Specialty Systems mentor-protégé JV all…
-
Sellas Life Sciences rises after reporting encouraging AML clinical results
Sellas Life Sciences Group Inc. (NASDAQ:SLS) advanced 4% in premarket trading Monday after unveiling new Phase 2 data for its investigational therapy SLS009 in acute myeloid leukemia with myelodysplastic syndrome–related changes (AML-MR). In patients who had previously been treated with venetoclax-based regimens, SLS009 — a CDK9 inhibitor — combined with azacitidine and venetoclax produced a…
-
PureTech slides after FDA meeting outlines next steps for IPF program
PureTech Health PLC (NASDAQ:PRTC) dropped 8.1% in Monday’s premarket trading after providing an update on its End-of-Phase 2 discussions with the FDA regarding deupirfenidone, a potential treatment for idiopathic pulmonary fibrosis (IPF). The company said regulators are supportive of moving into a pivotal Phase 3 study and pursuing a 505(b)(2) regulatory pathway through its Founded…
-
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results
Lyell Immunopharma Inc. (NASDAQ:LYEL) gained 4.2% in premarket trading Monday after the company released encouraging new data from its cancer therapy programs. The biotech reported that its CAR T-cell candidate, rondecabtagene autoleucel (ronde-cel), achieved a 93% overall response rate and a 76% complete response rate in patients with large B-cell lymphoma treated in the third-line…
-
Structure Therapeutics surges as oral GLP-1 candidate delivers standout weight-loss results
Structure Therapeutics Inc. ADR (NASDAQ:GPCR) soared 28.8% in Monday’s premarket trading after releasing strong topline results from its ACCESS clinical program evaluating aleniglipron, an oral GLP-1 receptor agonist being developed for obesity. In the Phase 2b ACCESS trial, the 120 mg dose produced a placebo-adjusted mean weight reduction of 11.3% (27.3 lbs) at 36 weeks.…
-
Evaxion Biotech gains after unveiling encouraging AML vaccine findings
Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its acute myeloid leukemia (AML) vaccine candidate, EVX-04. At the American Society of Hematology Annual Meeting in Orlando, the company reported that EVX-04 generated robust T-cell activation and effectively suppressed tumor growth in preclinical models. EVX-04 is an off-the-shelf…
-
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis
Cogent Biosciences Inc. (NASDAQ:COGT) surged 12.6% in Monday’s premarket session after unveiling encouraging top-line findings from APEX Part 2, its registration-directed Phase 2/3 study evaluating bezuclastinib in advanced systemic mastocytosis (AdvSM). The company reported a 57% objective response rate based on mIWG criteria and an 80% response rate per PPR criteria. Additionally, 89% of patients…
-
BioNTech advances premarket as lung cancer candidate delivers survival edge
BioNTech SE (NASDAQ:BNTX) traded 3.1% higher in Monday’s premarket session after the company, alongside partner OncoC4, released encouraging survival data for its investigational lung cancer therapy, gotistobart. The selective Treg-modulating drug produced a marked survival advantage in patients with previously treated squamous non-small cell lung cancer (sqNSCLC) when compared with standard chemotherapy. With nearly 15…